simethicone and Flatulence

Topics: Aerophagy; Antifoaming Agents; Colic; Colonic Diseases, Functional; Combined Modality Therapy; Constipation; Diet; Dietary Fiber; Diffusion; Eructation; Fermentation; Flatulence; Gases; Gastrointestinal Motility; Intestines; Parasympatholytics; Simethicone

An increase in intestinal gas production due to small intestinal bowel overgrowth (SIBO) is a contributing factor for flatus incontinence. The aims of our study were to assess the efficacy of metronidazole in a select population of patients with flatus incontinence associated with SIBO and to compare its efficacy with that of a combination of simethicone and activated charcoal (SC; Carbosylane) in randomized experimental arms.. Adult patients suffering from flatus incontinence associated with SIBO diagnosed by a glucose breath test were enrolled in the study. They were given metronidazole or Carbosylane (SC) for 10 days. The reduction in the mean daily number of gas leakages reported in a 3-day diary before and at the end of the treatment was used as the primary endpoint.. Of 52 consecutive subjects with flatus incontinence, 23 (44%) had SIBO, 16 (33%) of whom were included in and completed the study. The relative reduction in flatus incontinence episodes was significantly higher in the metronidazole than in the SC group (66.8±34.8% vs. 25±50%, P = 0.03), decreasing by more than 50% in 7 (87.5%) of the subjects in the metronidazole group compared with only 1 (12.5%) in the SC group (odds ratio 1.9, 95% confidence interval 0.9-56.9, P = 0.06).. Our results show a promising trend indicating that metronidazole might significantly improve flatus incontinence associated with SIBO and might be more successful in treating flatus incontinence than gas absorbents.

Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Charcoal; Drug Administration Schedule; Fecal Incontinence; Female; Flatulence; Gases; Gastrointestinal Microbiome; Glucose; Humans; Intestine, Small; Male; Metronidazole; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; Quality of Life; Simethicone; Treatment Outcome

To compare efficacy and tolerability of a loperamide/simethicone (LOP/SIM) combination product with that of loperamide (LOP) alone, simethicone (SIM) alone, and placebo (PBO) for acute nonspecific diarrhea with gas-related abdominal discomfort.. In this multicenter, double-blind, 48-h study, patients were randomly assigned to receive two tablets, each containing either LOP/SIM 2 mg/125 mg (n = 121), LOP 2 mg (n = 120), SIM 125 mg (n = 123), or PBO (n = 121), followed by one tablet after each unformed stool, up to four tablets in any 24-h period. The primary outcome measures were time to last unformed stool and time to complete relief of gas-related abdominal discomfort. For time to last unformed stool, an unformed stool after a 24-h period of formed stools or no stools was considered a continuance of the original episode (stricter definition) or a new episode (alternate definition).. A total of 483 patients were included in the intent-to-treat analysis. The median time to last unformed stool for LOP/SIM (7.6 h) was significantly shorter than that of LOP (11.5 h), SIM (26.0 h), and PBO (29.4 h) (p < or = 0.0232 in comparison with survival curves) using the alternate definition; it was numerically but not significantly shorter than that of LOP (p = 0.0709) and significantly shorter than that of SIM and PBO (p = 0.0001) using the stricter definition. LOP/SIM-treated patients had a shorter time to complete relief of gas-related abdominal discomfort than patients who received either ingredient alone or placebo (all p = 0.0001). Few patients reported adverse events in the four treatment groups, none of which were serious in nature. Potential study limitations include the ability to generalize study results to the population at large, variability in total dose consumed, and subjectivity of patient diary data.. LOP/SIM was well-tolerated and more efficacious than LOP alone, SIM alone, or placebo for acute nonspecific diarrhea and gas-related abdominal discomfort.

Topics: Abdominal Pain; Acute Disease; Adolescent; Adult; Aged; Antidiarrheals; Antifoaming Agents; Diarrhea; Double-Blind Method; Drug Combinations; Female; Flatulence; Gases; Humans; Intestines; Loperamide; Male; Middle Aged; Placebos; Simethicone; Treatment Outcome

Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Female; Flatulence; Humans; Image Enhancement; Male; Middle Aged; Pancreas; Pancreatic Pseudocyst; Simethicone; Ultrasonography

The results of studies of the effect of simethicone on abdominal gas-related symptoms have been contradictory. In a randomized, double-blind cross-over study, 10 healthy volunteers were given 30 g lactulose and 600 mg simethicone or placebo. End-expiratory breath samples were collected and analyzed for H2 and gastrointestinal symptoms registered. There were no differences in biochemical parameters or symptom score between simethicone and placebo. In contrast to previous studies, we used a sufficiently large dose of lactulose to produce gastrointestinal symptoms, a higher dose of simethicone and placebo tablets containing the same additives as the simethicone tablets. There was no demonstrable effect of simethicone on symptoms or intestinal gas production caused by carbohydrate malabsorption.

Topics: Adult; Breath Tests; Double-Blind Method; Female; Flatulence; Gastrointestinal Diseases; Humans; Hydrogen; Lactulose; Male; Simethicone

Topics: Adult; Antifoaming Agents; Atrial Fibrillation; Flatulence; Humans; Male; Precipitating Factors; Simethicone

Topics: alpha-Galactosidase; Evidence-Based Medicine; Flatulence; Gastrointestinal Agents; Humans; Probiotics; Rifamycins; Rifaximin; Salicylates; Simethicone

Topics: Child; Child, Preschool; Consumer Product Safety; Drug Contamination; Flatulence; Humans; Infant; Play and Playthings; Radio; Simethicone

Topics: Antidiarrheals; Antifoaming Agents; Carum; Cholestyramine Resin; Dietary Fiber; Flatulence; Humans; Irritable Bowel Syndrome; Loperamide; Physician-Patient Relations; Phytotherapy; Polyethylene Glycols; Simethicone

Topics: Adult; Drug Evaluation; Female; Flatulence; Gases; Humans; Infant; Infant, Newborn; Intestines; Simethicone

Topics: Anti-Bacterial Agents; Charcoal; Diet; Fabaceae; Feces; Flatulence; Humans; Hypnotics and Sedatives; Parasympatholytics; Plants, Medicinal; Simethicone

Topics: Animals; Antifoaming Agents; Flatulence; Intestines; Polysorbates; Silicones; Simethicone; Stomach; Surface-Active Agents

Topics: Flatulence; Humans; Pain, Postoperative; Silicones; Simethicone

Topics: Flatulence; Humans; Silicones; Simethicone

Topics: Cathartics; Constipation; Diet; Diet Therapy; Flatulence; Geriatrics; Humans; Magnesium Hydroxide; Simethicone; Syndrome